Voxelotor is an HbS polymerization inhibitor that reversibly binds to hemoglobin to stabilize the oxygenated hemoglobin state. 14,15 Once-daily oral administration of voxelotor has been shown to ...

Voxelotor 300mg; tabs for oral susp; grape flavor. Voxelotor is a hemoglobin S (HbS) polymerization inhibitor that binds to HbS and exhibits preferential partitioning to red blood cells. By ...

Sickle cell disease results from a homozygous missense mutation in the β-globin gene that causes polymerization of hemoglobin S. Gene therapy for patients with this disorder is complicated by the ...

Through a process called hemoglobin polymerization, red blood cells become sickled – deoxygenated, crescent-shaped and rigid.4-6 The sickling process causes hemolytic anemia (low hemoglobin due ...

Fetal hemoglobin is resistant to polymerization and, when present in sufficient quantity, is thought to disrupt the polymerization of sickle cell hemoglobin. Using these new models, ...

In the U.S., the hemoglobin S (HbS) polymerization inhibitor was granted accelerated approval for SCD in 2019 based on data from the phase III HOPE trial, which showed a better hemoglobin response ...

The company's flagship product, Voxelotor, is an oral, once-daily therapy that modulates hemoglobin’s affinity for oxygen, which is hypothesized to inhibit hemoglobin polymerization in patients ...

OXBRYTA works by increasing hemoglobin’s affinity for oxygen. OXBRYTA inhibits sickle hemoglobin polymerization and the resultant sickling and destruction of red blood cells leading to ...

The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD.